Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis
- PMID: 30393477
- PMCID: PMC6209727
- DOI: 10.5114/aoms.2017.68821
Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis
Abstract
Non-alcoholic fatty liver disease (NAFLD) refers to fatty infiltration of liver in the absence of significant alcohol intake, use of steatogenic medication, or hereditary disorders. It is a common cause of chronic liver disease with a worldwide estimated prevalence ranging from 6.3% to 33%. The NAFLD is considered a hepatic manifestation of the metabolic syndrome. Insulin resistance and increased oxidative stress are central to pathogenesis of NAFLD, and risk factors include metabolic syndrome, diabetes mellitus, obesity, lack of physical activity, smoking, and high fat diet. NAFLD is associated with higher mortality as compared to the general population with cardiovascular disease being the most common cause of death. The NAFLD is associated with a higher prevalence of subclinical atherosclerosis as evidenced by odds of higher coronary artery calcification, higher average and maximum carotid intima-media thickness. It is also associated with stiff arteries as evidenced by higher cardio-ankle vascular index and higher brachial-ankle pulse wave velocity. Increasing evidence has linked NAFLD with atherosclerotic cardiovascular diseases. The NAFLD is associated with a higher prevalence of coronary artery disease (CAD), more severe CAD, poor coronary collateral development, and higher incidence of coronary events. The NAFLD is also associated with ischemic stroke. Studies have shown that the association between NAFLD and atherosclerotic cardiovascular diseases is independent of shared risk factors.
Keywords: atherosclerotic cardiovascular disease; coronary artery disease; non-alcoholic fatty liver disease.
Similar articles
-
Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old.BMC Cardiovasc Disord. 2018 Jul 16;18(1):147. doi: 10.1186/s12872-018-0877-2. BMC Cardiovasc Disord. 2018. PMID: 30012085 Free PMC article.
-
Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.World J Gastroenterol. 2014 Oct 7;20(37):13306-24. doi: 10.3748/wjg.v20.i37.13306. World J Gastroenterol. 2014. PMID: 25309067 Free PMC article. Review.
-
Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study.J Hepatol. 2018 May;68(5):1018-1024. doi: 10.1016/j.jhep.2017.12.012. Epub 2017 Dec 20. J Hepatol. 2018. PMID: 29274406
-
A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis.PLoS One. 2022 May 31;17(5):e0269265. doi: 10.1371/journal.pone.0269265. eCollection 2022. PLoS One. 2022. PMID: 35639744 Free PMC article.
-
Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis.Rev Esp Enferm Dig. 2015 Jan;107(1):10-6. Rev Esp Enferm Dig. 2015. PMID: 25603326 Review.
Cited by
-
The effect of camelina oil (α-linolenic acid) and canola oil (oleic acid) on lipid profile, blood pressure, and anthropometric parameters in postmenopausal women.Arch Med Sci. 2020 Mar 31;17(6):1566-1574. doi: 10.5114/aoms.2020.94033. eCollection 2021. Arch Med Sci. 2020. PMID: 34900035 Free PMC article.
-
The Maternal and Fetal Consequences of Metabolic Dysfunction-Associated Fatty Liver Disease and Gestational Diabetes Mellitus.Nutrients. 2025 May 20;17(10):1730. doi: 10.3390/nu17101730. Nutrients. 2025. PMID: 40431469 Free PMC article. Review.
-
Association of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease with FADS2 rs3834458 Gene Polymorphism in the Chinese Han Population.Gastroenterol Res Pract. 2019 Nov 3;2019:6069870. doi: 10.1155/2019/6069870. eCollection 2019. Gastroenterol Res Pract. 2019. PMID: 31781193 Free PMC article.
-
In-Hospital Outcomes of Patients With Non-Alcoholic Fatty Liver Disease Who Underwent Percutaneous Coronary Intervention: A Nationwide Inpatient Sample Analysis.Cureus. 2021 Aug 20;13(8):e17338. doi: 10.7759/cureus.17338. eCollection 2021 Aug. Cureus. 2021. PMID: 34430188 Free PMC article.
-
A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation.Biochem Biophys Rep. 2023 Nov 1;36:101571. doi: 10.1016/j.bbrep.2023.101571. eCollection 2023 Dec. Biochem Biophys Rep. 2023. PMID: 37965066 Free PMC article. Review.
References
-
- Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811–26. - PubMed
-
- Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015;15:607. - PubMed
-
- Caturelli E, Squillante MM, Andriulli A, et al. Hypoechoic lesions in the ‘bright liver’: a reliable indicator of fatty change. A prospective study. J Gastroenterol Hepatol. 1992;7:469–72. - PubMed
-
- Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–50. - PubMed
-
- Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56:1384–91. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous